Lung cancer in HIV infected patients

Since the beginning of the AIDS epidemic our group has contributed to improving the knowledge concerning the impact of HIV infection in the lung. Several of these contributions have been published in Thorax as editorials, original articles and a review. In continuing this effort, we have recently published in Thorax a review entitled “Lung cancer in HIV infected patients: facts, questions and challenges.” The main objective of this educational review was to alert pulmonologists to a possible increase in the incidence of lung cancer in the HIV-positive population and to underline the facts that lung cancer occurring in young patients, may be less directly related to smoking and is probably associated with a worse outcome. This review included 103 references which were almost all original articles, six of which were from our group. However, during the time between submitting it to Thorax and publication in the journal, another review on the same topic was also published by our group in Lung Cancer. Even though there are strong similarities between the content of these two articles, the form of them is totally different. Furthermore, the review published in Thorax contained 29 additional references which were discussed in the paper. Unfortunately, during the process of reviewing the proof we omitted to include the article in press in Lung Cancer. We wish to apologise to the Editor of Thorax and the readers of the journal for this omission.

Jacques Cadranel, Charles Mayaud
Service de Pneumologie et Réanimation Thoracique, Hôpital Tenon, 4 rue de la Chine 75970, Paris Cedex 20, France; jacques.cadranel@thn.ap-hop-paris.fr

References

Safety and tolerability of three consecutive bronchoscopies after allergen challenge in patients with mild asthma

Ethical and safety considerations limit the design of studies with more than two consecutive fiberoptic bronchoscopies (FOBs) in patients with asthma. We present data on the safety and tolerability of three consecutive bronchoscopies at baseline, and 24 h and 7 days after allergen provocation. The study included 15 volunteers with mild asthma (9 men and 6 women); median age 25 (range 19–46) years; percentage predicted forced expiratory volume in 1 s (FEV1) 97% (75.4–123.7%); and a mean provocative concentration of methacholine causing a 20% fall in FEV1 (~PC20) of 2.1 (95% confidence interval (CI) 1.2 to 3.6) mg/ml at baseline FOB, 0.93 (95% CI 0.38 to 2.2) mg/ml at 24 h (p = 0.08) 0.90 (95% CI 0.45 to 1.8) mg/ml at 7 days (p = 0.03) after the allergen challenge.

FOB was not associated with a significant fall in FEV1 at baseline (median FEV1 93.9% predicted (range 80–120.1%) before FOB and 92.8% predicted (73.6–119.0%) at discharge). However, there was a significant reduction in median (range) percentage predicted FEV1 after FOB performed both 24 h and 7 days after the inhaled allergen challenge: 94.9% (75.1–111.1%) before FOB and 85.5% (62.4–119%) at discharge, p = 0.04, 24 h post challenge; and 100.1% (70.56–119%) before FOB, falling to 90.2% (66.2–119%) 7 days later, p = 0.009. We found a correlation between the percentage of instilled bronchoalveolar lavage volume recovered and change in FEV1 at discharge (r = 0.31, p = 0.04) when comparing combined data for all three bronchoscopies.

The median (range) pre-FOB oxygen saturation on room air was 99% (95–100%), with no significant change at discharge (97% (96–100%), p = 0.25). During FOB, the median (range) maximum oxygen saturation recorded was 98% (96–100%), whereas the minimum was 96% (92–100%). End procedure median (range) saturation was 98% (91–100%) on 2–4 l supplemental oxygen. Oxygen saturation on room air 10 min post procedure was maintained at a median (range) of 98% (95–99%).

The median (range) oxygen saturation pre-FOB on room air was 99% (96–100%) at 24 h after the allergen challenge and 97% (94–100%) at discharge (p = 0.02). The peak median (range) oxygen saturation recorded was 99% (98–100%) and the lowest level recorded was 96% (94–100%). The end median (range) saturation was 97% (93–100%) on 2–4 l of entrained oxygen, whereas the saturation on room air 10 min post procedure was 98% (94–100%).

The median (range) pre-FOB oxygen saturation was 98.5% (96–100%) at 7 days and 97.5% (96–100%) at discharge (p = 0.05). The highest recorded median (range) oxygen saturation was 99.5% (98–100%) and the lowest was 96% (92–98%). No clinical consequence as a result of desaturation was seen during the course of bronchoscopy.

We found no significant correlation between the change in oxygen saturation and the percentage volume of bronchoalveolar lavage recovered.

Table 1 summarises the effects of FOB on asthma control the day after bronchoscopy. FOB was associated with increased symptoms on all occasions. A significant fall in FEV1 was seen only after FOB that was preceded by an allergen challenge (p = 0.002) and was associated with the most significant increases in symptoms (p = 0.001) and corresponding drug usage (p = 0.004). None of these changes required treatment other than inhaled short-acting b2-agonists and all had resolved by the second day after FOB. Of the 15 volunteers, 12 returned for follow-up 2–6 weeks after the end of the study. The median (range) percentage predicted FEV1 was 99.88% (79–109%) at follow-up compared with 95.18% (75.41–114.8%) measured at the study entry screening visit. All 12 of these volunteers were still maintained on short-acting b2-agonists only and none reported clinical deterioration of asthma control in the weeks after the study.

A Barry Kay
Leukocyte Biology Section, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Summary of the effect of bronchoscopy on asthma control in terms of percentage predicted forced expiratory volume in 1 s, symptom scores and frequency of reliever drugs recorded the day before and the day after fiberoptic bronchoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOB</td>
<td>Day before FOB*</td>
</tr>
<tr>
<td>FOB1</td>
<td>FEV1%</td>
</tr>
<tr>
<td></td>
<td>Symptom score</td>
</tr>
<tr>
<td></td>
<td>Reliever drug frequency</td>
</tr>
<tr>
<td>FOB2</td>
<td>FEV1%</td>
</tr>
<tr>
<td></td>
<td>Symptom score</td>
</tr>
<tr>
<td></td>
<td>Reliever drug frequency</td>
</tr>
<tr>
<td>FOB3</td>
<td>FEV1%</td>
</tr>
<tr>
<td></td>
<td>Symptom score</td>
</tr>
<tr>
<td></td>
<td>Reliever drug frequency</td>
</tr>
</tbody>
</table>

Notes: *FEV1* forced expiratory volume in 1 s; FOB, fiberoptic bronchoscopy; NS, not significant.

The data shown are in patients who did not receive inhaled short-acting b2-agonists and who had a 24 h symptom score of 0. The data were collected at baseline and at the end of treatment. The results were then compared with the end of the study. The median (range) frequency of reliever drug usage recorded the day before and the day after bronchoscopy.

*Values are median (range).*
Lung cancer in HIV infected patients

Jacques Cadranel and Charles Mayaud

Thorax 2007 62: 557

Updated information and services can be found at:
http://thorax.bmj.com/content/62/6/557.1

These include:

References
This article cites 8 articles, 7 of which you can access for free at:
http://thorax.bmj.com/content/62/6/557.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/